Helocyte, Inc.

Helocyte is a clinical-stage biopharmaceutical company developing novel immunotherapies for the prevention and treatment of cancer and infectious disease (and in particular, cytomegalovirus or “CMV”). The Centers for Disease Control estimate that 50 to 80 percent of Americans are infected with CMV by the age of 40. While the virus is asymptomatic in healthy individuals, it can cause severe and life-threatening disease in those with weakened or uneducated immune systems. Patients undergoing stem cell and solid organ transplantation are at particularly high risk of experiencing complications associated with CMV. Helocyte’s Triplex is a First-in-Class, Best-in-Class MVA-based vaccine engineered to induce a robust and durable virus-specific T cell response to control CMV in transplant recipients. Helocyte’s ConVax is designed to induce both neutralizing antibody and T cell responses for prevention and control of CMV. There is no approved immunotherapy for the prevention or treatment of CMV. While current antiviral therapies have reduced the rate of CMV disease-related mortality in transplant recipients, such treatments have been linked to increased toxicity, delayed immune reconstitution and late onset of CMV. The Helocyte vaccines can educate the body’s immune system to fight CMV. For more information, please visit www.helocyte.com.